CA-DENODO
18.5.2021 09:02:11 CEST | Business Wire | Press release
Data virtualization leader Denodo’s fourth annual cloud usage survey finds organizations are accelerating their cloud journey to take advantage of its flexibility, control costs, speed time-to-market, and simplify data management. According to survey respondents, which included 150 global business and IT professionals from various industry sectors, hybrid-cloud deployment remains the dominant choice, as more than a third of these organizations (35 percent) use this model. Private cloud has shown some vibrant usage, accounting for almost a quarter of all workloads (24 percent), followed by public cloud, which remained almost flat at 16 percent. Multi-cloud remains a popular choice for almost one in ten organizations (9 percent) who opt to procure best of breed applications, data repositories, and infrastructure orchestration technologies among different cloud service providers to avoid a single vendor lock-in.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210518005232/en/
The complimentary findings are available for download here .
Even though the number of organizations with some level of cloud adoption remained steady year-over-year, the percentage of organizations that are moving advanced workloads to the cloud has increased by 25 percent (19.59 percent in 2021 vs. 15.48 percent in 2020). While security and skills are still major concerns for organizations, the statistics clearly indicates that businesses are becoming more confident about moving their important workloads to the cloud and embracing cloud more than ever. In terms of cloud providers, AWS and Azure still hold the lion’s share of the cloud market (65 percent combined), while others like Google Cloud Platform (GCP) are slowly catching up.
As a sizeable percentage of organizations are cautiously putting their first step into the cloud, Marketplaces are becoming very popular as almost half (45 percent) are leveraging them to take advantage of various incentives, including low upfront investments and risks. Utility/pay-as-you-go pricing is the most popular motivation at 35 percent followed by its self-service capability/ability to minimize IT dependency (25 percent), and simplified procurement (14 percent). Avoiding a long-term commitment was also a motivator at 6 percent.
Companies are using cloud for various use cases with the top two popular being analytics and infrastructure usage, and AI/ML. AI/ML and stream processing use cases are showcasing their importance on how businesses are using those technologies for their day-to-day operations, as year-over-year growth for each ranged between 50 and 100 percent. Close to 50 percent of participants leverage multiple solutions for data integration in the cloud, the most popular ones being data lakes, ETL pipeline, cloud data warehouse and object storage.
As organizations embrace cloud faster than ever, IT processes are becoming more automated and agile through the adoption of microservices and containers. Fifty percent of survey respondents indicated that they are using Docker for automation and portability. Kubernetes adoption is also increasing at a steady pace, because for many organizations, hundreds and at times thousands of microservices span both on-premises IT environments and multiple clouds.
“While we already know that cloud has become an inevitable force in IT infrastructure management, with cloud migration challenges abound, organizations often do not have a clear path to cloud adoption,” said Ravi Shankar, senior vice president and chief marketing officer of Denodo. “For the last four years, our audience has been sharing how they see the path to a successful infrastructure modernization unfolding. Just like majority of our audience, I personally believe that a well laid out logical data fabric, created with data virtualization, may be the key to helping organizations embrace a hybrid or multi-cloud strategy that is easy to deploy, manage, and maintain.”
Methodology:
The 2021 Denodo Global Cloud Study surveyed 150 organizations in March 2021. Users from various backgrounds, roles and regions participated. The full report is available for download here .
Please Tweet: New survey from #datavirtualization leader @denodo reveals advanced workloads moving to the #cloud as organizations embrace #hybrid and #multi-cloud architectures
About Denodo
Denodo is the leader in data virtualization providing agile, high performance data integration, data abstraction, and real-time data services across the broadest range of enterprise, cloud, big data, and unstructured data sources at half the cost of traditional approaches. Denodo’s customers across every major industry have gained significant business agility and ROI by enabling faster and easier access to unified business information for agile BI, big data analytics, Web, cloud integration, single-view applications, and enterprise data services. Denodo is well-funded, profitable, and privately held. For more information, visit http://www.denodo.com or call +1 877 556 2531 / +44 (0) 20 7869 8053.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210518005232/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
REPLY: The Board of Directors Approves the Quarterly Report Dated 31 March 202615.5.2026 13:38:00 CEST | Press release
All economic and financial indicators grew:Consolidated revenues of €645.0 million (€607.5 million in 2025);EBITDA of €112.0 million (€105.3 million in 2025);EBIT of €95.1 million (€88.7 million in 2025);Profit before tax amounts to €99.8 million (€86.9 million in 2025). Today, the Board of Directors of Reply S.p.A. [EXM, STAR: REY] approved the results as at 31 March 2026. Since the beginning of the year, the Group has recorded a consolidated revenues amounting to €645.0 million, an increase of 6.2% compared to the corresponding data for 2025. All indicators are positive for the period. In the first quarter of 2026 the consolidated EBITDA stood at €112.0 million compared to €105.3 million in 2025, equal to 17.4% of the turnover. EBIT, from January to March, was €95.1 million (€88.7 million in 2025) and is equal to 14.7% of the turnover. The profit before tax, from January to March, was €99.8 million (€86.9 million in 2025), equal to 15.5% of the turnover. The net financial position of
Organon to Present New Research on Access and Value at ISPOR 202615.5.2026 13:30:00 CEST | Press release
New findings will highlight contraception affordability, biosimilar adoption, and access-focused analyses across the women’s health and general medicines portfolio Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, will present data across women’s health, biosimilars, dermatology, and neurology at ISPOR 2026, the leading global scientific conference hosted by the International Society for Pharmacoeconomics and Outcomes Research. The conference, focused on health economics and outcomes research, will take place May 17-20, 2026, in Philadelphia, Pennsylvania. Across 8 accepted abstracts, the data reflect Organon’s commitment to generating real-world evidence—rooted in lived experiences—that can help inform healthcare decision-making and improve health outcomes across a range of therapeutic areas. “Health economics and outcomes research is critical to ensuring the right treatments reach patients and that
SES Announces Extraordinary General Meeting of Shareholders15.5.2026 08:30:00 CEST | Press release
SES: Société Anonyme RCS Luxembourg B 81267 Notice is hereby given of the Extraordinary General Meeting of SES, Société Anonyme, to be held at the Company's registered office at Château de Betzdorf, L-6815 Betzdorf (the "Company"), Luxembourg, on Wednesday 17 June 2026 at 3:00 p.m. CET AGENDA Attendance list, quorum and adoption of the agenda Nomination of a secretary and of two scrutineers Cancellation of shares purchased in connection with the buy-back programme of 2 November 2023, as amended on 2 May 2024, in accordance therewith and pursuant thereto - Reduction of the share capital in accordance with article 450-5 of the law of 10 August 1915 on commercial companies, as amended, by forty-four million nine hundred ten thousand seven hundred eighty euro (EUR 44,910,780) through the cancellation of thirty-five million nine hundred and twenty-eight thousand six hundred and twenty-four (35,928,624) shares divided into (i) twenty-three million nine hundred and fifty-two thousand four hun
Experian Partners With ServiceNow to Scale Trusted Decisioning to Agentic AI15.5.2026 08:00:00 CEST | Press release
New global long‑term partnership embeds Experian’s Ascend capabilities directly into ServiceNow workflows, transforming client operations Experian, the global data and technology company, and ServiceNow (NYSE: NOW), the AI control tower for business reinvention, today unveil a new global multi-year partnership which harnesses the power of autonomous AI agents across platforms, helping businesses make faster and smarter decisions at scale. Through this partnership, autonomous AI agents can gain the ability to act faster, and more consistently, starting with employee onboarding, third-party risk management and model life cycle governance use cases. A major challenge for global organisations adopting agentic AI is achieving scale, with deployments often constrained by a lack of trusted data. In fact, industry research shows that data limitations are the primary barrier for eight in ten organisations. By connecting trusted intelligence directly into enterprise workflows, this partnership e
Meiji Seika Pharma: Positive Results from the Phase III Integral-1 Trial of Nacubactam, a Novel β-Lactamase Inhibitor, in Complicated Urinary Tract Infections or Acute Uncomplicated Pyelonephritis ― Published in The Lancet15.5.2026 03:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (headquartered in Tokyo; President and Representative Director: Toshiaki Nagasato) today announced that the results of the Integral-1 study, one of two global Phase III clinical trials evaluating the efficacy and safety of its novel β-lactamase inhibitor nacubactam (development code: OP0595), have been published in The Lancet. The article is entitled “---Efficacy and safety of cefepime–nacubactam and aztreonam–nacubactam compared with imipenem–cilastatin for complicated urinary tract infection or acute uncomplicated pyelonephritis (Integral-1): a double-blind, randomised phase 3 trial” (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00596-9/fulltext) Integral-1 is a global, double-blind, randomized Phase III trial (jRCT2031230075) in patients with complicated urinary tract infection or acute uncomplicated pyelonephritis that compared the efficacy and safety of nacubactam co-administered with either cefepime or aztreonam versus imipenem-c
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
